What
is CaVenT study?
Long-term outcome after additional catheter-directed thrombolysis versus
standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT
study): a randomised controlled trial. 209 patients were randomly
assigned to treatment groups (108 control, 101 CDT). At completion of 24
months' follow-up, data for clinical status were available for 189 patients
(90%; 99 control, 90 CDT). At 24 months, 37 (41·1%, 95% CI 31·5—51·4) patients
allocated additional CDT presented with PTS compared with 55 (55·6%, 95% CI
45·7—65·0) in the control group (p=0·047). The difference in PTS corresponds to
an absolute risk reduction of 14·4% (95% CI 0·2—27·9), and the number needed to
treat was 7 (95% CI 4—502). Iliofemoral patency after 6 months was reported in
58 patients (65·9%, 95% CI 55·5—75·0) on CDT versus 45 (47·4%, 37·6—57·3) on
control (p=0·012). 20 bleeding complications related to CDT included three
major and five clinically relevant bleeds.
from University of Oslo.
No comments:
Post a Comment